Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.
复制标题
DOI：
10.1016/j.leukres.2009.02.005
复制
发表时间：
2009-12
影响因子：
2.7
通讯作者：
Ma X
中科院分区：
文献类型：
--
作者：
Wang R;Gross CP;Halene S;Ma X
骨髓增生异常综合征（MDS）患者的共病情况很少进行系统研究。我们进行了一项大规模人群研究，以评估合并症在新诊断MDS患者生存中的作用。本研究纳入了2001-2002年在美国诊断的1，708例MDS患者（年龄≥ 66岁），随访至2004年底。使用多变量考克斯比例风险模型估计风险比（HR）。中位生存时间约为18个月。51%的MDS患者有合并症。合并症患者的死亡风险显著高于无合并症患者。对于Charlson指数为1-2和≥ 3的患者，HR分别为1.19（95%置信区间[CI]：1.05-1.36）和1.77（95% CI：1.50-2.08）。死亡风险随着Charlson指数的增加而增加。患有充血性心力衰竭或慢性阻塞性肺病的MDS患者的生存期明显短于没有这些条件的患者，而糖尿病似乎对生存期没有影响。这项研究证实了合并症是MDS生存率的一个重要和独立的决定因素，研究结果强调了在评估MDS预后时考虑合并症的重要性。
Comorbid conditions have rarely been systematically studied among patients with myelodysplastic syndromes (MDS). We conducted a large population-based study to assess the role of comorbidity in the survival of newly diagnosed MDS patients. This study included 1,708 MDS patients (age ≥ 66 years) diagnosed in the US during 2001–2002, with follow-up through the end of 2004. Hazard ratios (HRs) were estimated using multivariate Cox proportional hazard models. The median survival time was approximately 18 months. Fifty one percent of MDS patients had comorbid conditions. Patients with comorbid conditions had significantly greater risk of death than those without comorbidities. The HR was 1.19 (95% confidence interval [CI]: 1.05–1.36) and 1.77 (95% CI: 1.50–2.08) for those with a Charlson index of 1–2 and ≥ 3, respectively. The risk of death increases with Charlson index. MDS patients who have congestive heart failure or chronic obstructive pulmonary disease had significantly shorter survival than patients without those conditions, whereas diabetes did not appear to have an impact on survival. This study confirms comorbidity as a significant and independent determinant of MDS survival, and the findings underscore the importance to take comorbid conditions into account when assessing the prognosis of MDS.
登录
查看更多内容
影响因子：
20.3
作者：
Maris, MB;Sandmaier, BM;Maloney, DG
通讯作者：
Maloney, DG
影响因子：
6.2
作者：
Ma, Xiaomei;Does, Monique;Mayne, Susan T.
通讯作者：
Mayne, Susan T.
影响因子：
7.2
作者：
ROMANO, PS;ROOS, LL;JOLLIS, JG
通讯作者：
JOLLIS, JG
影响因子：
20.3
作者：
Greenberg, P;Cox, C;Bennett, J
通讯作者：
Bennett, J
影响因子：
50.5
作者：
Jacot, W.;Colinet, B.;Pujol, J. -L.
通讯作者：
Pujol, J. -L.